Lts Lohmann Therapie-systeme Ag

Ucb Pharma Gmbh

Ucb Manufacturing Ireland Limited

Ucb Biopharma Sprl

Walter Müller

Michael Horstmann

Hans-Michael Wolff

Thomas Hille

Hans-Rainer Hoffmann

Christoph Arth

Luc Quere

Johannes Josef Leonhard

James V Peck

Reinhold Meconi

Patrick Mohr

Marco Emgenbroich

Dietrich Wilhelm Schacht

Horst Dzekan

Sandra Wiedersberg

Thomas Lauterbach

Robert P Klein

Kristina Kassner

Willi Cawello

The present invention relates to a transdermal therapeutic system, comprising (a) a backing layer, (b) a solvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, wherein the self-adhesive matrix layer has a coating weight of about 75-400 g/mand comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer, a kit comprising two transdermal therapeutic systems of the present invention as well as a method for the preparation of the transdermal therapeutic system of the present invention. In addition, the present invention relates to a transdermal therapeutic system comprising rotigotine as active ingredient for use in the treatment of patients suffering from Parkinson's disease, Parkinson's plus syndrome, depression, fibromyalgia and the restless-legs syndrome and for use in the treatment or prevention of dopaminergic neuron loss or cognitive disorders by transdermal administration of rotigotine once or twice weekly, wherein the transdermal therapeutic system comprises a backing layer, a solvent-based rotigotine containing self-adhesive matrix layer as well as a release liner and is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.

Multi-day patch for the transdermal administration of rotigotine

The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.

Transdermal therapeutic system with fentanyl or related substances

The invention relates to a transdermal therapeutic system on the basis of polysiloxane which contains microreservoirs filled with an active substance and one ambiphilic solvent.

Microreservoir system based on polysiloxanes and ambiphilic solvents

The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine

A substantially solvent-free matrix layer containing (&#x2212;)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol is produced by adding an active substance to an adhesive solution, coating the resultant active substance-containing adhesive solution onto a suitable sheet, and removing the solvents in a drying process to give said substantially solvent-free matrix layer.

Transdermal therapeutic system and method of use thereof for treating parkinsonism

The invention generally relates to a transdermal therapeutic system which comprises a backing layer, an adhesive layer, a polymer layer and a removable protective layer. The adhesive layer is an organosiloxane layer that is anchored to the backing layer by siliconization.

Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer

Transdermal or topical plasters containing active ingredient are provided that include a non-occlusive back layer, a matrix formed from of one or more polymer layers having at least one pharmaceutical active ingredient in one or more of the layers, in which the structure-forming base polymers of the layer(s) are non-occlusive or only slightly occlusive and a second polymer that has a low water-vapor permeability and that is immiscible or only very slightly miscible with the base polymer is dispersed in at least one of the polymer layers.

Plaster having adjustable occlusion

The invention relates to a topical patch comprising a therapeutic compound-impermeable backing layer, a self-adhesive matrix based on polysiloxanes and containing capsaicin or a therapeutic compound analogous to capsaicin, and a protective film to be removed before use, in which the matrix contains liquid microreservoirs based on an amphiphilic solvent, in which the therapeutic compound is present in completely dissolved form and the concentration of the therapeutic compound in the microreservoir droplets is below the saturation concentration. The invention furthermore relates to a process for its production and its use in the treatment of neuropathic pain.

Therapeutic patch for transdermal delivery of capsaicin

The invention relates to a transdermal therapeutic systems with fentanyl or an analogous fentanyl derivative as active ingredient. In order to prevent inadvertent overdosage by uncontrolled release of active ingredient as a result of damage, the active ingredient is contained in fluid-filled micro-reservoirs in the layer containing the active ingredient. The layer containing the active ingredient can optionally be provided with a membrane.

Transdermal therapeutic system (TTS) with fentanyl as a active ingredient

A transdermal therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising a backing layer, a reservoir supersaturated with active ingredients which is attached to said backing layer and prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, and a detachable protective layer, is characterized in that the crystallization inhibitor is an amino-containing polymer.

Growing community of inventors

Andernach, Germany

Walter Müller